- The global antihypertensive drugs market was valued at around $20.5 billion in 2021 and is expected to reach $39.5 billion by 2030, growing at a CAGR of 2.95%
- Lexaria’s patented DehydraTECH(TM) technology is designed to formulate and deliver lipophilic drugs and active pharmaceutical ingredients (“APIs”), increasing effectiveness and improving how drugs are delivered into the bloodstream
- DehydraTECH is suitable for use with a wide range of product formats, including pharmaceuticals, nutraceuticals, and over-the-counter capsules, pills, tablets, or oral suspensions
- Lexaria is continuing to evaluate the results of its HYPER-H21-4 human clinical study and will report additional findings as they become available
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced additional findings from its human clinical study HYPER-H21-4, demonstrating a potentially novel mechanism of action of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) capsule formulation in reducing blood pressure. The FDA lays out clear guidelines for sponsors seeking to develop new anti-hypertension drugs, specifically defining the need for medications that offer complimentary modes of action. Lexaria believes that its latest results, detailed in the peer-reviewed and published in the journal “Biomedicine and Pharmacotherapy,” may support DehydraTECH-CBD qualification within the FDA guidelines (https://cnw.fm/vSYeP).
The global antihypertensive drugs market was valued at around $20.5 billion in 2021. The market is expected to grow at a CAGR of 2.95% between 2022 and 2030, resulting in a value of $39.5 billion, as a result of a worldwide increase in the number of hypertension cases. Hypertension is a common but…
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.cbdwire.com
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.